Core Viewpoint - The announcement from Haohai Biological Technology indicates that the company's actual controller, Jiang Wei, has been penalized for insider trading, with a total fine and confiscation amounting to 19.34 million yuan. The company asserts that this matter is unrelated to its operations and will not significantly impact its business or financials [2][3]. Group 1: Regulatory Actions - Jiang Wei received an administrative penalty from the China Securities Regulatory Commission (CSRC) for insider trading, with a confiscation of illegal gains amounting to 4.71 million yuan and a fine of 14.63 million yuan, totaling 19.34 million yuan [2][3]. - The penalty is directed at Jiang Wei personally, and the company emphasizes that it is not involved in the matter, as Jiang does not participate in daily management [2][3]. Group 2: Company Background - Haohai Biological Technology was established in 2007 and listed on the Hong Kong Stock Exchange in 2015, later becoming the first company to be listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board in October 2019 [2][3]. - The company primarily engages in the production and sales of biopharmaceuticals, including medical sodium hyaluronate gel, epidermal growth factor, chitosan, collagen, artificial crystals, and ophthalmic implants [3]. Group 3: Financial Performance - For the first three quarters of 2025, Haohai Biological Technology reported total revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down over 10% [4]. - The net cash flow from operating activities for the same period was 377 million yuan, reflecting a decline of 12.45% year-on-year, attributed to insufficient domestic consumer demand, price competition, and tax rate adjustments [4]. Group 4: Capital Operations - Despite the investigation of its actual controller, Haohai Biological Technology continued its capital operations, announcing on November 9 that it plans to acquire the remaining 20% stake in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for 74 million yuan, which would result in the company holding 100% of the target company's equity [5].

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has a current stock price of 56.75 yuan, with a rolling PE ratio of 31.94, marking a new low in 94 days, and a total market capitalization of 13.199 billion yuan [1] Company Summary - Haohai Biological specializes in the research, production, and sales of medical devices and pharmaceuticals, with key products including ophthalmic viscoelastic devices, artificial lenses, optical materials, hyaluronic acid, and medical chitosan [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.312 million yuan, down 7.41%, with a gross profit margin of 69.52% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Haohai Biological at 61st place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Haohai Biological Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of June 3, the company's stock closed at 53.32 yuan, with a rolling PE ratio of 30.09, marking a new low in 28 days, and a total market value of 12.434 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Haohai Biological at the 66th rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 619 million yuan, reflecting a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% year-on-year, with a gross margin of 69.52% [1] - As of the Q1 2025 report, three institutions hold shares in Haohai Biological, with a total of 2.4635 million shares valued at 146 million yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2024年度已審財務報表》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年3月21日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 上海昊海生物科技股份有限公司 已审财务报表 2024年度 ...